-
公开(公告)号：US06673337B2
公开(公告)日：2004-01-06
申请号：US10299386
申请日：2002-11-19
IPC分类号： A61K3174
CPC分类号： A61K31/734 , A61K9/0048 , A61K31/498 , A61K31/715 , A61K31/716 , A61K31/78 , A61K47/32 , A61K47/38 , A61K31/495 , A61K31/717 , A61K2300/00
摘要： Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.
摘要翻译： 可用于改善α-2-肾上腺素能激动剂组分的有效性的组合物包括载体组分，α-2-肾上腺素能激动剂组分，有助于增溶α-2-肾上腺素能激动剂组分的溶解度增强组分。 在一个实施方案中，α-2-肾上腺素能激动剂组分包括α-2-肾上腺素能激动剂。 在另一个实施方案中，增溶溶解成分包括羧甲基纤维素。
-
公开(公告)号：US06723353B2
公开(公告)日：2004-04-20
申请号：US09989295
申请日：2001-11-20
IPC分类号： A61K3314
CPC分类号： A61K47/02 , A61K9/0048 , A61K47/40
摘要： Compositions including a liquid medium, a cyclodextrin component and a preservative component which has a reduced tendency to being complexed with the cyclodextrin component. In one embodiment, the preservative component is a chlorite component. Active components, such as pharmaceutically active components or drugs, preferably are included in the compositions.
摘要翻译： 包括液体介质，环糊精组分和防腐剂组分的组合物，其具有降低与环糊精组分复合的倾向。 在一个实施方案中，防腐剂组分是亚氯酸盐组分。 活性组分，例如药物活性组分或药物，优选包括在组合物中。
-
公开(公告)号：US06627210B2
公开(公告)日：2003-09-30
申请号：US09904018
申请日：2001-07-10
IPC分类号： A61K3314
CPC分类号： A61K31/734 , A61K9/0048 , A61K31/498 , A61K31/715 , A61K31/716 , A61K31/78 , A61K47/32 , A61K47/38 , A61K31/495 , A61K31/717 , A61K2300/00
摘要： Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.
-
公开(公告)号：US06358935B1
公开(公告)日：2002-03-19
申请号：US09388968
申请日：1999-09-02
IPC分类号： A61K31715
CPC分类号： A61K47/02 , A61K9/0048 , A61K47/40
摘要： Compositions including a liquid medium, a cyclodextrin component and a preservative component which has a reduced tendency to being complexed with the cyclodextrin component. In one embodiment, the preservative component is a chlorite component. Active components, such as pharmaceutically active components or drugs, preferably are included in the compositions.
摘要翻译： 包括液体介质，环糊精组分和防腐剂组分的组合物，其具有降低与环糊精组分复合的倾向。 在一个实施方案中，防腐剂组分是亚氯酸盐组分。 活性组分，例如药物活性组分或药物，优选包括在组合物中。
-
公开(公告)号：US06641834B2
公开(公告)日：2003-11-04
申请号：US10236566
申请日：2002-09-06
IPC分类号： A61K3314
CPC分类号： A61K31/734 , A61K9/0048 , A61K31/498 , A61K31/715 , A61K31/716 , A61K31/78 , A61K47/32 , A61K47/38 , A61K31/495 , A61K31/717 , A61K2300/00
摘要： Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.
-
公开(公告)号：US06562873B2
公开(公告)日：2003-05-13
申请号：US09903962
申请日：2001-07-10
IPC分类号： A61K4732
CPC分类号： A61K9/0048 , A61K31/4164 , A61K31/498
摘要： Compositions which include therapeutically active components, solubility enhancing components other than cyclodextrins, and oxy-chloro components, wherein the oxy-chloro components are substantially effective as preservatives. In one embodiment, the oxy-chloro components are useful for preserving the therapeutically active components. In one embodiment, the oxy-chloro components include chlorite components. In a useful embodiment, the solubility enhancing components include carboxymethylcellulose.
-
7.发明授权公开(公告)号：US08257730B2
公开(公告)日：2012-09-04
申请号：US11118288
申请日：2005-04-29
申请人： Glenn T. Huang , Thierry Nivaggioli , Lon T. Spada , Hiroshi Sugimoto , Wendy M Blanda , James N. Chang , Orest Olejnik
发明人： Glenn T. Huang , Thierry Nivaggioli , Lon T. Spada , Hiroshi Sugimoto , Wendy M Blanda , James N. Chang , Orest Olejnik
IPC分类号： A61F2/00
CPC分类号： A61K9/0051 , A61K9/0092 , A61K31/573 , A61K31/58 , A61K45/06 , A61K2300/00
摘要： Biocompatible intraocular implants include a steroid and a polymer associated with each other to facilitate release of the steroid into an eye for a period of time greater than about two months. The steroid may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants may be placed in an eye to treat one or more ocular conditions. The steroid is released from the implant for more than about two months, and may be release for more than several years.
摘要翻译： 生物相容性眼内植入物包括彼此相关的类固醇和聚合物，以促进类固醇进入眼睛大于约两个月的时间。 类固醇可以与可生物降解的聚合物基质相关联，例如两种可生物降解聚合物的基质。 或者，类固醇可以与具有一个或多个开口有效以允许类固醇释放到外部环境中的聚合物涂层相关联。 植入物可以放置在眼睛中以治疗一种或多种眼睛状况。 类固醇从植入物中释放超过约两个月，可能会释放超过几年。
-
公开(公告)号：US08007828B2
公开(公告)日：2011-08-30
申请号：US12577114
申请日：2009-10-09
申请人： Patrick M. Hughes , Orest Olejnik
发明人： Patrick M. Hughes , Orest Olejnik
IPC分类号： A61K9/14
CPC分类号： A61K9/0024 , A61K9/0051 , A61K9/204 , A61K38/4893
摘要： Biodegradable neurotoxin implants and methods of making and using such implants are provided. Biodegradable neurotoxin implants include a neurotoxin, a biodegradable polymer component, and an acidity regulating component. The biodegradable polymer component is effective in controlling the release of the neurotoxin from the implant when the implant is located in a patient's body. The acidity regulating component is effective in maintaining a pH of the implant in a desired range that may be effective in stabilizing the neurotoxin as the implant biodegrades when the implant is located in a patient's body. In one embodiment, an implant includes a botulinum toxin, a biodegradable polymer, and either monomers from which a biodegradable polymer is derived or oligomers including monomeric units substantially identical to a monomer from which a biodegradable polymer is derived, or a combination of such monomers and oligomers. The oligomers and biodegradable polymer may be derived from a single type of monomer. The implants disclosed herein may be administered to a human or animal patient in which a therapeutic effect is desired for prolonged periods of time.
摘要翻译： 提供了可生物降解的神经毒素植入物和制造和使用这种植入物的方法。 可生物降解的神经毒素植入物包括神经毒素，可生物降解的聚合物组分和酸度调节组分。 当植入物位于患者体内时，可生物降解的聚合物组分有效地控制来自植入物的神经毒素的释放。 酸性调节组分有效地将植入物的pH保持在期望的范围内，当植入物位于患者体内时，当植入物生物降解时，稳定神经毒素是有效的。 在一个实施方案中，植入物包括肉毒杆菌毒素，可生物降解聚合物，以及衍生生物可降解聚合物的单体或包含单体单元的寡聚物，所述单体基本上与衍生可生物降解聚合物的单体相同，或这些单体和 低聚物。 低聚物和可生物降解的聚合物可以衍生自单一类型的单体。 本文公开的植入物可以施用于需要长时间治疗效果的人或动物患者。
-
9.发明申请公开(公告)号：US20100222587A1
公开(公告)日：2010-09-02
申请号：US12730102
申请日：2010-03-23
IPC分类号： C07D403/12
CPC分类号： A61K31/557 , A61K9/0048 , A61K31/498 , A61K31/513 , A61K47/542 , A61K47/549 , A61K47/55 , A61K47/551 , A61K47/64
摘要： Membrane transporter-targeted therapeutic agents and methods of making and using the same.
摘要翻译： 膜转运体靶向治疗剂及其制备和使用方法。
-
公开(公告)号：US20080145407A1
公开(公告)日：2008-06-19
申请号：US11932373
申请日：2007-10-31
申请人： Glenn T. Huang , Thierry Nivaggioli , Lon T. Spada , Hiroshi Sugimoto , Wendy M. Blanda , James N. Chang , Orest Olejnik
发明人： Glenn T. Huang , Thierry Nivaggioli , Lon T. Spada , Hiroshi Sugimoto , Wendy M. Blanda , James N. Chang , Orest Olejnik
CPC分类号： A61K9/0051 , A61F9/0017 , A61K9/0024 , A61K9/0092 , A61K9/1647 , A61K9/204 , A61K31/5377 , A61K31/56 , A61K31/573 , A61K31/58 , A61K45/06 , A61K47/593 , A61L27/18 , A61L27/54 , A61L27/58 , A61L31/06 , A61L31/148 , A61L31/16 , A61L2300/222 , A61L2300/436 , A61L2300/45 , A61L2300/604 , A61L2430/16 , A61K2300/00 , C08L67/04
摘要： Biocompatible intraocular implants include a steroid and an auxiliary agent, where the auxiliary agent is present in an amount sufficient to lessen the severity of at least one side effect compared to the use of an otherwise identical implant lacking said auxiliary agent. The steroid and the auxiliary agent may be present on the same intraocular implant or on different implants. The steroid and auxiliary agent may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants containing the steroid and an auxiliary agent may be placed in an eye to treat one or more ocular conditions while reducing the side effects otherwise accompanying steroid use.
摘要翻译： 生物相容性眼内植入物包括类固醇和辅助剂，其中与使用缺乏所述辅助剂的其它相同的植入物相比，辅助剂的存在量足以减轻至少一种副作用的严重性。 类固醇和辅助剂可以存在于相同的眼内植入物或不同的植入物上。 类固醇和辅助剂可以与可生物降解的聚合物基质相结合，例如两种可生物降解的聚合物的基质。 或者，类固醇可以与具有一个或多个开口有效以允许类固醇释放到外部环境中的聚合物涂层相关联。 包含类固醇和辅助剂的植入物可以放置在眼睛中以治疗一种或多种眼部病症，同时减少否则伴随类固醇使用的副作用。
-
-
-
-
-
-
-
-
-
搜索结果
94 条记录 (耗时 0.032 秒)
